John Maraganore steps in­to a new role at an up­start biotech as the god­fa­ther phase of his ca­reer takes shape

John Maraganore isn’t wast­ing any time shift­ing to a new post-Al­ny­lam phase in his long biotech ca­reer. Start­up wun­derkind Beam Ther­a­peu­tics has lured the soon-to-be ex-CEO to its board, where Maraganore can be­gin to play god­fa­ther to the next gen­er­a­tion of biotechs look­ing to fol­low his foot­steps from the lab to the mar­ket­place.

In se­lect­ing the Beam of­fer — and it’s un­like­ly there will be any kind of short­age on that front — Maraganore will now play god­fa­ther to an up­start out of David Liu’s lab look­ing to do new things in gene edit­ing. That fits snug­ly with Maraganore’s in­ten­tion of step­ping back from the day-to-day grind of the C-suite while ad­vis­ing star­tups on the long road ahead. And it’s a coup for Beam CEO John Evans, as every face on the board rep­re­sents an­oth­er op­por­tu­ni­ty to build cred­i­bil­i­ty and at­tract new in­vestors.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE